Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody and pembrolizumab.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling.

Abstract: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from administration of one or more hedgehog inhibitors, alone or in combination with therapeutic agents; to predict a time course of disease or a probability of a significant event in the disease of a cancer patient; to stratify patient populations; and/or to more effectively treat or prevent a cancer or a tumor associated with hedgehog signaling.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method and system for organizing and storing map data that facilitates use of the map data by navigation application programs such as those in navigation systems. The map data represent geographic features located in a region. The map data are organized into parcels such that each parcel contains a portion of the map data. The map data contained in each parcel represent those geographic features contained in a corresponding separate one of a plurality of rectangular areas located in the region. Each rectangular area has a uniform dimension in a first coordinate direction but has a dimension in the other coordinate direction such that the map data that represent the geographic features contained in the rectangular area are close to, but do not exceed, a maximum data size for a parcel.

Abstract: A method that facilitates complying with traffic restrictions that involve three or more connected road segments when using a navigation system to determine a route. The method includes forming multiple instances of data representing each intermediate road segment between an entrance segment and an exit segment and storing data defining restrictions that apply to only two connected road segments, such that a valid driving paths exists between the entrance segment and the intermediate segment and between the intermediate segment and the exit segment, but that no valid driving paths exist between the entrance segment and the exit segment.